A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study.

摘要: Acitretin, the free acid of etretinate, is less lipophilic and has a much shorter terminal half-life than parent compound. The present double-blind, randomized study compared therapeutic effectiveness tolerability acitretin (n = 127) etretinate 41) in psoriasis. Patients were treated with 40 mg daily for first 4 weeks an individually adjusted dose subsequent 8 weeks. average doses (0.54 mg/kg/day) (0.65 similar. PASI (Psoriasis Area Severity Index) scores improved parallel 2 treatment groups. At completion study, score improvement was 75.8% 70.8% etretinate. Both resulted mucocutaneous side effects. Assessments by investigators patients showed statistically significant difference favour These results demonstrate that have similar Although tolerance to lower offers important advantage period potential teratogenicity is, therefore, be preferred women childbearing potential.